CRB Inverbío is a venture capital management firm specialized in early stage life science investments. Founded in 2010, the company manages two venture capital funds: Cross Road Biotech SCR, fully invested, focused on seed biotech spin offs and CRB Bio II, an early stage life science fund that invests in promising bio and med tech companies. CRB Inverbío has currently 13 companies in its portfolio including some of the most promising life science companies in Spain including: • TCD Pharma: an oncology company with a first in class phase II ready small molecule for solid tumors • Venter Pharma: commercializing worldwide a new non-invasive diagnostic test for the qualitative and quantitave determination of hypolactasia and lactose intolerance • OWL: a biotechnology company with a leading position in personalized medicine through the application of metabolomics to biomarker discovery, and has introduced in the market the first in vitro serum based diagnostic for NASH • Biocross: Non-invasive serum based high precision (>90%) multiparametric diagnostic test for Alzheimer´s disease, combining metabolites, peptides and genetic markers • Oncovision, a company focused on Molecular Vision and Medical Imaging • Amadix, a company developing cancer molecular diagnostics • Raman Health Technologies, developing a new non invasive diagnostic technology platform based on Raman laser and Infrarred spectroscopy for the early diagnosis of Alzheimer disease and other applications • Iden Technologies, that develops technology for crop yield improvement and plant stress resistance • Health In Code, focused on molecular genetic diagnosis of familial cardiac diseases • Nuubo, the company designs, manufactures and sells a proprietary portfolio of innovative wearable wireless medical technologies for cardiac prevention, diagnosis and rehabilitation • Mecwins, developing a proprietary technology for nanomechanical biosensing.